Cargando…

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C

BACKGROUND: It has been found that ITPase deficiency is caused by ITPA gene polymorphisms. It was observed that ITPA polymorphisms have impact on hematological changes, including hemoglobin (Hb)-decline during treatment of chronic hepatitis C (CHC) patients with pegylated-interferon (PEG-IFN) plus r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pouryasin, Mohammad, Keshvari, Maryam, Sharafi, Heidar, Alavian, Seyed Moayed, Behnava, Bita, Alavian, Seyed Ehsan, Pouryasin, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851836/ https://www.ncbi.nlm.nih.gov/pubmed/27148387 http://dx.doi.org/10.5812/hepatmon.35278

Ejemplares similares

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study
por: Sharafi, Heidar, et al.
Publicado: (2014)

The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C
por: Behnava, Bita, et al.
Publicado: (2016)

Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals
por: Sharafi, Heidar, et al.
Publicado: (2012)

Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
por: Sharafi, Heidar, et al.
Publicado: (2012)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C
por: Kadjbaf, Danesh, et al.
Publicado: (2016)

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
por: Dolatimehr, Fardin, et al.
Publicado: (2017)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
por: Sharafi, Heidar, et al.
Publicado: (2020)

What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?
por: Keshvari, Maryam, et al.
Publicado: (2014)

Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2014)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis
por: Alavian, Seyed-Moayed, et al.
Publicado: (2012)

How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level?
por: Keshvari, Maryam, et al.
Publicado: (2014)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?
por: Sharafi, Heidar, et al.
Publicado: (2018)

IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients
por: Sharafi, Heidar, et al.
Publicado: (2011)

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders
por: Sharafi, Heidar, et al.
Publicado: (2021)

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials
por: Aminizadeh, Ehsan, et al.
Publicado: (2016)

Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2014)

Low Dose Ribavirin for Treatment of Hepatitis C Virus Infected Thalassemia Major Patients; New Indications for Combination Therapy
por: Tabatabaei, Seyed Vahid, et al.
Publicado: (2012)

A Woman with Recent Jaundice and Pruritus
por: Behnava, Bita, et al.
Publicado: (2010)

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta
por: Keshvari, Maryam, et al.
Publicado: (2014)

Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis
por: Rajabi, Abdolhalim, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran
por: Mehrazmay, Alireza, et al.
Publicado: (2013)

The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2010)

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
por: Mahdavi, Meisam, et al.
Publicado: (2013)

IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report
por: Mahboobi, Nastaran, et al.
Publicado: (2011)

Lipid Profiles and Hepatitis C Viral Markers in HCV-Infected Thalassemic Patients
por: Alavian, Seyed-Moayed, et al.
Publicado: (2011)

Appropriate Genotyping of Hepatitis B Virus in Iran
por: Jazayeri, Seyed Mohammad, et al.
Publicado: (2015)

Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran
por: Namazee, Najmeh, et al.
Publicado: (2012)

Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis
por: Ghaderi-Zefrehi, Hossein, et al.
Publicado: (2016)

Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B
por: Bakhshizadeh, Fatemeh, et al.
Publicado: (2015)

Distribution of Human Papillomavirus Genotypes in Liquid-based Samples; Abundance of HPV-53 in Tehran, Iran
por: POURYASIN, Mohammad, et al.
Publicado: (2014)

Plasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?
por: Abbasinazari, Mohammad, et al.
Publicado: (2013)

Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
por: Moradi, Ghobad, et al.
Publicado: (2021)

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
por: Tasavon Gholamhoseini, Mohammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pv10p5p757eur0elnpos72ppuo